Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children [PDF]
Frontiers in Pediatrics, 2023 BackgroundAngiopoietin-like 3 (ANGPTL3) is a secretory glycoprotein. It has been demonstrated that ANGPTL3 level was upregulated in minimal change nephrotic syndrome (MCNS) kidney tissues.
Fujie Wen +11 more
doaj +2 more sources
Serum Angiopoietin-like Protein 3 Levels Are Associated with Endothelial Function in Patients with Maintenance Hemodialysis [PDF]
Life, 2023 Angiopoietin-like protein 3 (ANGPTL3) plays an important role in lipid and lipoprotein trafficking and metabolism and is positively correlated with cardiovascular disease.
Tzu-Chiang Wu +4 more
doaj +2 more sources
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia [PDF]
Clinical Pharmacology: Advances and Applications, 2022 Constantine E Kosmas,1,2 Maria D Bousvarou,3 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,2 Rogers Echavarria Uceta,2 Eliscer Guzman1,2 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA ...
Kosmas CE +6 more
doaj +2 more sources
Positive correlation of serum angiopoietin-like protein 3 levels with metabolic syndrome in patients with coronary artery disease [PDF]
Tzu Chi Medical Journal, 2022 Objectives: Angiopoietin-like protein 3 (ANGPTL3) regulates triglyceride metabolism by reversibly inhibiting the lipoprotein lipase activity. Metabolic syndrome (MetS) is an independent risk factor for further cardiovascular disease. This study evaluated
Sy-Harn Lian +3 more
doaj +2 more sources
Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice [PDF]
Journal of Lipid Research, 2021 Supported by an abundance of experimental and genetic evidence, angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising therapeutic target for cardiovascular disease. ANGPTL3 is primarily produced by the liver and is a potent modulator of plasma
Thomas A. Bell, III +5 more
doaj +2 more sources
Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria [PDF]
Lipids in Health and Disease, 2019 Background Angiopoietin-like protein 3(ANGPTL3) is well acknowledged as a key regulator of lipid metabolism. Now, there have not been enough data to explain the mechanism of hyperlipidemia related proteinuria.
Xia Gao +6 more
doaj +2 more sources
Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance [PDF]
Journal of Lipid Research, 2020 Angiopoietin-like protein (ANGPTL)3 regulates plasma lipids by inhibiting LPL and endothelial lipase (EL). ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway and represents a promising therapeutic approach for ...
Rene C. Adam +15 more
doaj +2 more sources
Serum Angiopoietin-like Protein 3 Level Is Associated with Peripheral Arterial Stiffness in Patients with Coronary Artery Disease [PDF]
Medicina, 2021 Background and Objectives: Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating lipid metabolism. This study evaluated the relationship between serum ANGPTL3 level and peripheral arterial stiffness (PAS) in patients with coronary ...
Chien-Hao Hsiao +3 more
doaj +2 more sources
On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity
Journal of Lipid Research, 2019 Angiopoietin-like (ANGPTL) 8 is a secreted inhibitor of LPL, a key enzyme in plasma triglyceride metabolism. It was previously reported that ANGPTL8 requires another member of the ANGPTL family, ANGPTL3, to act on LPL.
Oleg Kovrov +4 more
doaj +3 more sources
Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism1[S] [PDF]
Journal of Lipid Research, 2016 The consequences of angiopoietin-like protein 3 (ANGPTL3) deficiency on postprandial lipid and lipoprotein metabolism has not been investigated in humans.
Ilenia Minicocci +14 more
doaj +2 more sources